The risk and outcomes of pneumonia in patients on inhaled corticosteroids

Oriol Sibila; Natalia Soto-Gomez; Marcos I. Restrepo

doi:10.1016/j.pupt.2015.04.001

The risk and outcomes of pneumonia in patients on inhaled corticosteroids

Oriol Sibila
, Natalia Soto-Gomez
, Marcos I. Restrepo

Department of Medicine

Producción científica: Article › revisión exhaustiva

20 Citas (Scopus)

Resumen

Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes.

Idioma original	English (US)
Páginas (desde-hasta)	130-136
Número de páginas	7
Publicación	Pulmonary Pharmacology and Therapeutics
Volumen	32
DOI	https://doi.org/10.1016/j.pupt.2015.04.001
Estado	Published - jun 1 2015

ASJC Scopus subject areas

Biochemistry, medical
Pharmacology (medical)
Pulmonary and Respiratory Medicine

Acceder al documento

10.1016/j.pupt.2015.04.001

Otros archivos y enlaces

Citar esto

@article{d94b2083d25844ecb6046c9687412948,

title = "The risk and outcomes of pneumonia in patients on inhaled corticosteroids",

abstract = "Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes.",

keywords = "Chronic obstructive pulmonary disease, Inhaled corticosteroids, Pneumonia",

author = "Oriol Sibila and Natalia Soto-Gomez and Restrepo, \{Marcos I.\}",

note = "Publisher Copyright: {\textcopyright} 2015.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.pupt.2015.04.001",

language = "English (US)",

volume = "32",

pages = "130--136",

journal = "Pulmonary Pharmacology and Therapeutics",

issn = "1094-5539",

publisher = "Academic Press",

}

TY - JOUR

T1 - The risk and outcomes of pneumonia in patients on inhaled corticosteroids

AU - Sibila, Oriol

AU - Soto-Gomez, Natalia

AU - Restrepo, Marcos I.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes.

AB - Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes.

KW - Chronic obstructive pulmonary disease

KW - Inhaled corticosteroids

KW - Pneumonia

UR - https://www.scopus.com/pages/publications/84930509134

UR - https://www.scopus.com/pages/publications/84930509134#tab=citedBy

U2 - 10.1016/j.pupt.2015.04.001

DO - 10.1016/j.pupt.2015.04.001

M3 - Article

C2 - 25956073

AN - SCOPUS:84930509134

SN - 1094-5539

VL - 32

SP - 130

EP - 136

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

ER -

The risk and outcomes of pneumonia in patients on inhaled corticosteroids

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto